The Collaborators, which include Alnylam employees and payers, regulators and government employees, are working to ensure that people around the world who may benefit from innovative RNAi therapeutics, have access to them. An important component of access is Alnylam’s Patient Access Philosophy, and innovative pricing agreements such as Value Based Agreements.